Salmonella LPS Inibitori

I comuni inibitori dell'LPS di Salmonella includono, a titolo esemplificativo, Polimixina B Solfato CAS 1405-20-5, Rifampicina CAS 13292-46-1, Chitosano CAS 9012-76-4, Bismuto(III) subsalicilato CAS 14882-18-9 e N-Acetil-L-cisteina CAS 616-91-1.

Salmonella is a genus of Gram-negative bacteria responsible for a range of diseases, from mild gastroenteritis to severe systemic infections. An important component of the outer membrane of Salmonella, as in many other Gram-negative bacteria, is lipopolysaccharide (LPS), often referred to as endotoxin. LPS plays a key role in the structural integrity of the bacterium and protects the cell from hostile environments. In addition, LPS is a potent immunostimulator and can trigger strong immune responses in the host, leading to inflammation. The O antigen, a part of the LPS molecule, is particularly variable and is often used to distinguish different serotypes of Salmonella.

Salmonella LPS inhibitors are a group of compounds specifically designed to target and neutralize Salmonella LPS, thereby decreasing its virulence and ability to cause disease. These inhibitors can work through a variety of mechanisms. For example, some may bind directly to LPS, blocking its interaction with host immune receptors and attenuating the inflammatory response. Others might interfere with LPS biosynthesis or transport, impairing the bacterial cell wall and making the bacterium more susceptible to environmental threats or host defenses. Another class of inhibitors could target the enzymes responsible for LPS modifications, which can affect the virulence and resistance of the bacterium. By focusing on LPS and associated pathways, these inhibitors may provide a targeted approach to combating Salmonella infections by addressing the bacterium's ability to thrive and induce disease in the host. The development and understanding of these inhibitors contribute to the broader scientific goal of understanding and combating microbial pathogens.